Interpore strikes development deal with Quantic:
This article was originally published in Clinica
Bone graft developer Interpore has agreed a licence and development deal with Quantic Biomedical, based in San Rafael, California. It gives Interpore rights to a technology that produces super-concentrated tissue growth factors derived from a patient's own blood. The two companies intend to develop a bone and cartilage repair product combining Interpore's Pro Osteon bone graft substitute with Quantic's autologous growth factor concentrates.